July 2016 - NAFLD/NASH
Read online or forward
 
   
 

Enjoy today's NAFLD/NASH news!




Nonalcoholic fatty liver disease (NAFLD) is to become the major reason for liver transplantation by 2030 and is the most common cause of chronic liver diseases in western countries.

NAFLD does not only affect the liver but was shown to be a multisystem disease with increased risk of type 2 diabetes, kidney, and cardiovascular diseases. 5-20% of NAFLD patients will develop steatohepatitis (NASH) with a risk of progression to cirrhosis and HCC.

Fighting this disease is now a real emergency. EASL through its different meetings, schools, publications (Journal of Hepatology, Clinical Practice Guidelines) and online educational tools (iLiver and LiverTree) strives to participate in the battle against NAFLD and NASH.

Discover future EASL events

EASL will host a Monothematic Conference in Ljubljana, Slovenia on ‘Nutrition in liver disease’.

Topics to be covered include patient management and nutrition in Alcoholic Liver Disease, NAFLD, IFALD and PNALD, Cirrhosis, ALF, Biliary diseases, and Fibrosis.

Submit your abstract. Deadline 26 August 2016!
 

Discover the EASL publications
on NAFLD/NASH

Have a look at the Journal's latest snapshot
on the diagnosis of NAFLD.



Did you know that EASL, EASD and EASO have produced Clinical Practice Guidelines on the diagnosis, treatment, and follow-up of non-alcoholic fatty liver disease?

Download your free copy! 
 
 

EASL
The Home of Hepatology

7 rue Daubin
CH 1203 Geneva
+41 22 807 03 60
www.easl.eu

This message is sent to <<Email Address>> - Why did I get this message

Update subscription preferences || Unsubscribe

You can sign in at any time by visiting the Newsletter section of our website.